Jeff Landau is currently the CEO of Stipple Bio. Mr. Landau has over 20 years of biopharmaceutical experience in corporate development, corporate strategy, and new product strategy and planning. Most recently, Mr. Landau was Chief Business Officer and Head of Strategy at CytomX Therapeutics where he was a member of the CytomX executive management team. Prior to joining CytomX, Mr. Landau was Senior Vice President of Corporate Development, Commercial, and New Product Strategy at Catalyst Biosciences and previously held roles of increasing responsibility at Threshold Pharmaceuticals and Onyx Pharmaceuticals (acquired by Amgen). Mr. Landau received his M.B.A. from Stanford Graduate School of Business and his B.S. with honors in biochemistry/biotechnology from Virginia Polytechnic Institute.